Articles by Steve Davis
-
Wednesday
May 8
2013One Step Closer to Ending Malaria: Public-private partnerships tap the potential of synthetic anti-malarial treatment
PATH and its partners in the public and private sector recently began producing a new synthetic version of artemisinin, the key ingredient in the gold-standard malaria treatment. This promises to bolster the existing botanical supply and meet approximately one-third of the global demand. According to PATH CEO Steve Davis, this milestone shows the strength of collaboration across the public and private sectors to advance science for the benefit of global health.
- Categories
- Health Care